Home LiteratureArticle Details
PMID: 19660658 Published · ppublish English Journal Article Review

Trophic factors therapy in Parkinson's disease.

Progress in brain research ·Vol. 175 ·2009-00-00 ·Pages 201-16

Ramaswamy S, Soderstrom KE, Kordower JH

Abstract

Parkinson's disease (PD) is a progressive, neurodegenerative disorder for which there is currently no effective neuroprotective therapy. Patients are typically treated with a combination of drug therapies and/or receive deep brain stimulation to combat behavioral symptoms. The ideal candidate therapy would be the one which prevents neurodegeneration in the brain, thereby halting the progression of debilitating disease symptoms. Neurotrophic factors have been in the forefront of PD research, and clinical trials have been initiated using members of the GDNF family of ligands (GFLs). GFLs have been shown to be trophic to ventral mesencephalic cells, thereby making them good candidates for PD research. This paper examines the use of GDNF and neurturin, two members of the GFL, in both animal models of PD and clinical trials.

MeSH Terms
Animals Clinical Trials as Topic Genetic Therapy/methods Humans Nerve Growth Factors/therapeutic use Parkinson Disease/therapy
Chemicals
Nerve Growth Factors
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Ramaswamy Shilpa
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Soderstrom Katherine E
Kordower Jeffrey H
References (46)
46 references, click to expand
  1. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8 PMID: 12122208
  2. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons.
    J Neurosci. 1998 Jul 1;18(13):4929-37 PMID: 9634558
  3. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.
    Mov Disord. 2007 Jun 15;22(8):1124-32 PMID: 17443702
  4. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.
    Mol Ther. 2007 Jan;15(1):62-8 PMID: 17164776
  5. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.
    Brain Res. 1995 Feb 20;672(1-2):104-11 PMID: 7749731
  6. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin.
    Exp Neurol. 2001 Mar;168(1):155-61 PMID: 11170730
  7. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Brain Res. 2002 Aug 30;947(2):271-83 PMID: 12176170
  8. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.
    J Neurosci. 2000 Jun 15;20(12):4686-700 PMID: 10844038
  9. Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum.
    Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):151-71 PMID: 10581409
  10. Point source concentration of GDNF may explain failure of phase II clinical trial.
    Exp Neurol. 2006 Dec;202(2):497-505 PMID: 16962582
  11. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy.
    Neuroreport. 1998 Jun 1;9(8):1817-22 PMID: 9665607
  12. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects.
    J Comp Neurol. 2003 Jun 23;461(2):250-61 PMID: 12724841
  13. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Exp Neurol. 1998 Dec;154(2):261-75 PMID: 9878166
  14. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.
    Exp Neurol. 2002 Oct;177(2):461-74 PMID: 12429192
  15. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
    Nat Med. 2003 May;9(5):589-95 PMID: 12669033
  16. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
    Ann Neurol. 2006 Mar;59(3):459-66 PMID: 16429411
  17. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
    J Neurosurg. 2007 Apr;106(4):614-20 PMID: 17432712
  18. Absolute requirement of GDNF for adult catecholaminergic neuron survival.
    Nat Neurosci. 2008 Jul;11(7):755-61 PMID: 18536709
  19. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.
    Neurobiol Dis. 2007 Jul;27(1):67-76 PMID: 17532642
  20. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.
    Neurology. 2003 Jan 14;60(1):69-73 PMID: 12525720
  21. Dopaminergic neurons protected from degeneration by GDNF gene therapy.
    Science. 1997 Feb 7;275(5301):838-41 PMID: 9012352
  22. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.
    Ann Neurol. 2006 Dec;60(6):706-15 PMID: 17192932
  23. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.
    Ann Neurol. 1999 Sep;46(3):419-24 PMID: 10482276
  24. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.
    Ann Neurol. 2005 Feb;57(2):298-302 PMID: 15668979
  25. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.
    Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8818-23 PMID: 9238061
  26. Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model.
    Eur J Neurosci. 2005 Nov;22(10):2587-95 PMID: 16307601
  27. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
    Eur J Neurosci. 1999 May;11(5):1554-66 PMID: 10215908
  28. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice.
    Brain Res Mol Brain Res. 2003 Jun 10;114(2):123-31 PMID: 12829322
  29. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
    Lancet Neurol. 2008 May;7(5):400-8 PMID: 18387850
  30. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
    Brain Res. 2007 Apr 20;1142:206-16 PMID: 17336273
  31. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.
    Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14083-8 PMID: 9391156
  32. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).
    Exp Neurol. 2003 Nov;184(1):536-48 PMID: 14637123
  33. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.
    Brain. 2002 Oct;125(Pt 10):2191-201 PMID: 12244077
  34. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.
    Science. 1993 May 21;260(5111):1130-2 PMID: 8493557
  35. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.
    Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8935-9 PMID: 7568047
  36. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
    Science. 2000 Oct 27;290(5492):767-73 PMID: 11052933
  37. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.
    Eur J Neurosci. 2000 Nov;12(11):3871-82 PMID: 11069582
  38. Trophic factor distribution predicts functional recovery in parkinsonian monkeys.
    Ann Neurol. 2005 Aug;58(2):224-33 PMID: 16049934
  39. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.
    Parkinsonism Relat Disord. 2007 Mar;13(2):77-88 PMID: 16963309
  40. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
    Gene Ther. 2002 Mar;9(6):381-9 PMID: 11960314
  41. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain.
    Nat Med. 2005 Jul;11(7):703-4 PMID: 16015352
  42. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons.
    J Neurochem. 1999 Jul;73(1):70-8 PMID: 10386956
  43. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys.
    Neurobiol Aging. 2002 Sep-Oct;23(5):881-9 PMID: 12392792
  44. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
    Neuroreport. 2002 Jan 21;13(1):75-82 PMID: 11924898
  45. Novel functions and signalling pathways for GDNF.
    J Cell Sci. 2003 Oct 1;116(Pt 19):3855-62 PMID: 12953054
  46. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
    Neurobiol Dis. 2004 Nov;17(2):283-9 PMID: 15474365
Article Info
Journal
Progress in brain research
Abbr.
Prog Brain Res
ISSN
1875-7855
DOI
10.1016/S0079-6123(09)17514-3
Published
2009-00-00
Pages
201-16
Language
English
Region
Netherlands
NLM ID
0376441
PMCID
PMC3430519
Subset
IM
Grants
NINDS NIH HHS · R01 NS055143 · United States
NINDS NIH HHS · R01 NS055143-01A1 · United States
External Links
PubMed source DOI: 10.1016/S0079-6123(09)17514-3 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2